Featured News

Anokion SA released successful results from their Phase 1 ACeD clinical trial and they will be moving forward with Phase 2 trials later this year.

We are pleased to announce that CDF Board Member, Kristin Yarema, PhD, was honored as a 2022 Medical Marketing & Media Woman of Distinction.

The Celiac Disease Foundation is pleased to announce the establishment of two international celiac disease research prizes to inspire a new generation of researchers whose work in celiac disease will be invaluable.

The Celiac Disease Foundation is in discussion with a team at the University of Colorado, Denver to develop the first-ever, FDA-approved pediatric PRO (patient-reported outcome tool).

A recent study found that avoidant/restrictive food intake disorder (ARFID) is common among people with celiac disease.

On April 8 and April 9, the Celiac Disease Foundation is sponsoring the Columbia University Celiac Disease Center International Symposium on Celiac Disease.

Join us at the Columbia University Celiac Connect Continuing Medical Education- April 1, and UChicago Neurological and Psychological Implications in Celiac Disease- April 23.

Researchers found that children initially diagnosed with potential celiac disease had a high risk of developing celiac disease.

A few highlights from research studies published in peer-reviewed journals in the last few months are products of the research grants CDF awarded.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.